Magnetic resonance imaging (MRI) is especially good at visualizing soft tissue in the body and is used in the investigation and monitoring of MS. With current methods, however, physicians are for the most part forced to make subjective judgments, or visual estimations, of the images, which can make it difficult to obtain a good and comparable measure of disease development. Patients with MS can develop brain atrophy, or a loss of brain tissue. SyMRI NEURO generates a quantitative measure of brain atrophy by automatic calculation of BPF, thus enabling objective monitoring of disease development. Linköping University Hospital is now installing SyMRI to improve the monitoring of MS patients. The hospital will initially conduct a pilot project with the aim of taking SyMRI into clinical use in Region Östergötland during 2016.

"With SyMRI we can get an automatic measurement of brain atrophy, which means that we can now quantify the neurodegeneration that occurs in connection with MS. This allows for a better follow-up for our patients", says Patrik Fägerstam, Neuroradiologist at Linköping University Hospital.

SyMRI NEURO will be installed in the hospital's PACS from Sectra.

For additional information, please contact Maria Wrethag, CMO and Head of investor relations SyntheticMR AB, +46 76 119 1983, or Stefan Tell, CEO SyntheticMR AB, +46 73 373 40 90.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has devloped SyMRI® IMAGE, software that provides fast MRI workflows, allowing high patient throughput, and SyMRI NEURO that enables automatic segmentation of brain tissue, providing objective decision support based on quantitative data. SyMRI is CE-marked product. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.symri.com .